Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

←Back to companies

HGH · NZX

Heartland Group Holdings (HGH)

Financials / Banking and finance•Covered: HY22 - HY26•9 published briefings

Heartland Group Holdings is an NZX-listed financials / banking and finance company with HY22 - HY26 of published result briefings.

Latest briefing

HY26 · Released 26 February 2026

NPAT rebuilt to NZ$48.8m as the NZ lending reset rolls off

The 1255.6% headline NPAT lift is recovery from a depressed comparable; underlying NPAT of NZ$46.1m and ROE of 7.8% set the cleaner read.

Market data

Latest available
Price
NZD 1.23
Mkt cap
$1.2b
Yield
4.5%

Quote as of 05-06-2026 4:40pm NZT

Sections⌄
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights

Snapshot

Latest metrics

HY26, released 26 February 2026

← Swipe to view more
HGH latest metrics
MetricValueChange
Revenue$172.3m↑ +10.9%
Operating profit$77.9m↑ +36.1%
NPAT$48.8m↑ +1255.6%
Operating cash flow$299.5m↑ +26.6%
OCF / Operating profit %384.7%↓ -28.8pp
Net debt-$387.9m↓ -138.6%
Net debt / Operating profit-4.98x↓ -128.3%
ROE %7.8%↑ +7.5pp
DPS3.5c↑ +75.0%
Payout ratio vs NPAT %67.3%Outside range lowOutside range low payout ratio versus npat. 67.3%; 4-period range 68.1% to 500%. Payout ratio versus NPAT: 67.3%, below normal range; 4-period mean 179.7%, range 68.1%-500.0%.↓ -432.7pp

Source: latest published briefing (HY26, released 26 February 2026). Change compares against the prior equivalent period: HY25, released 27 February 2025.

Chat

Ask about HGH

Ask follow-up questions about Heartland Group Holdings's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about HGH

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Longitudinal view

Performance over time

The latest period is shown first.

← Swipe to view more
HGH metric history
MetricHY266 MONTHS26 February 2026FY2512 MONTHS21 August 2025HY256 MONTHS27 February 2025FY2412 MONTHS29 August 2024HY246 MONTHS27 February 2024FY2312 MONTHS29 August 2023HY236 MONTHS28 February 2023FY2212 MONTHS23 August 2022HY226 MONTHS22 February 2022Trend
Revenue$172.3m$322.9m$155.3m$290.4m$141.2m$289.8m$144.2m$280.6m$130.8m
Chart
Revenue growth %11.1%Outside range highOutside range high revenue growth. 11.1%; 4-period range -2% to 10.2%. Revenue growth: 11.1%, above normal range; 4-period mean 6.8%, range -2.0%-10.2%.11.1%9.9%0.2%Outside range lowOutside range low revenue growth. 0.2%; 3-period range 3.3% to 11.7%. Revenue growth: 0.2%, below normal range; 3-period mean 8.7%, range 3.3%-11.7%.-2.0%Unprecedented lowUnprecedented low revenue growth. -2%; 4-period range 8.9% to 11.1%. Revenue growth: -2.0%, unprecedented low; 4-period mean 10.0%, range 8.9%-11.1%.3.3%10.2%11.7%Outside range highOutside range high revenue growth. 11.7%; 3-period range 0.2% to 11.1%. Revenue growth: 11.7%, above normal range; 3-period mean 4.9%, range 0.2%-11.1%.8.9%
Chart
  • HY24 Revenue growth %: Unprecedented low revenue growth. -2%; 4-period range 8.9% to 11.1%. Revenue growth: -2.0%, unprecedented low; 4-period mean 10.0%, range 8.9%-11.1%.
  • FY24 Revenue growth %: Outside range low revenue growth. 0.2%; 3-period range 3.3% to 11.7%. Revenue growth: 0.2%, below normal range; 3-period mean 8.7%, range 3.3%-11.7%.
  • HY26 Revenue growth %: Outside range high revenue growth. 11.1%; 4-period range -2% to 10.2%. Revenue growth: 11.1%, above normal range; 4-period mean 6.8%, range -2.0%-10.2%.
Operating profit$77.9m—$57.2m$151.3m—$161.7m$80.7m$163.9m$73.5m
Chart
Operating profit margin %45.2%—36.8%52.1%—55.8%56.0%58.4%56.2%
Chart
PBT$68.1m$57.2m$5.3m$104.5m$52.6m$134m$69m$137m$64.9m
Chart
PBT growth %n/m-45.3%Outside range lowOutside range low pbt growth. -45.3%; 3-period range -22% to 15.5%. PBT growth: -45.3%, below normal range; 3-period mean -2.9%, range -22.0%-15.5%.-89.9%-22.0%-23.8%-2.2%6.3%15.5%Outside range highOutside range high pbt growth. 15.5%; 3-period range -45.3% to -2.2%. PBT growth: 15.5%, above normal range; 3-period mean -23.2%, range -45.3%--2.2%.8.9%
Chart
  • FY25 PBT growth %: Outside range low pbt growth. -45.3%; 3-period range -22% to 15.5%. PBT growth: -45.3%, below normal range; 3-period mean -2.9%, range -22.0%-15.5%.
NPAT$48.8m$38.8m$3.6m$74.5m$37.6m$95.9m$48.7m$95.1m$47.5m
Chart
NPAT growth %n/m-47.9%Outside range lowOutside range low npat growth. -47.9%; 3-period range -22.3% to 9.3%. NPAT growth: -47.9%, below normal range; 3-period mean -4.1%, range -22.3%-9.3%.-90.4%-22.3%-22.8%0.8%2.5%9.3%Outside range highOutside range high npat growth. 9.3%; 3-period range -47.9% to 0.8%. NPAT growth: 9.3%, above normal range; 3-period mean -23.1%, range -47.9%-0.8%.7.7%
Chart
  • FY25 NPAT growth %: Outside range low npat growth. -47.9%; 3-period range -22.3% to 9.3%. NPAT growth: -47.9%, below normal range; 3-period mean -4.1%, range -22.3%-9.3%.
Operating cash flow$299.5m$673.2m$236.6m$928.4m-$8.8m$42.7m$262.2m-$262.3m-$142.3m
Chart
OCF / Operating profit %384.7%—413.5%613.7%—26.4%324.8%-160.1%-193.6%
Chart
FCF pre-lease$297.2m$668.8m$234.8m$900.3m-$25.5m$18m$254.4m-$272.1m-$150.9m
Chart
DPS3.5c2.0c2.0c3.0c4.0c6.0c5.5c5.5c5.5c
Chart
Payout ratio vs NPAT %67.3%Outside range lowOutside range low payout ratio versus npat. 67.3%; 4-period range 68.1% to 500%. Payout ratio versus NPAT: 67.3%, below normal range; 4-period mean 179.7%, range 68.1%-500.0%.96.6%Outside range highOutside range high payout ratio versus npat. 96.6%; 3-period range 68.2% to 82.4%. Payout ratio versus NPAT: 96.6%, above normal range; 3-period mean 73.9%, range 68.2%-82.4%.500.0%Unprecedented highUnprecedented high payout ratio versus npat. 500%; 4-period range 67.3% to 75.5%. Payout ratio versus NPAT: 500.0%, unprecedented high; 4-period mean 71.6%, range 67.3%-75.5%.71.1%75.5%82.4%75.3%68.2%Outside range lowOutside range low payout ratio versus npat. 68.2%; 3-period range 71.1% to 96.6%. Payout ratio versus NPAT: 68.2%, below normal range; 3-period mean 83.4%, range 71.1%-96.6%.68.1%
Chart
  • HY25 Payout ratio vs NPAT %: Unprecedented high payout ratio versus npat. 500%; 4-period range 67.3% to 75.5%. Payout ratio versus NPAT: 500.0%, unprecedented high; 4-period mean 71.6%, range 67.3%-75.5%.
  • FY25 Payout ratio vs NPAT %: Outside range high payout ratio versus npat. 96.6%; 3-period range 68.2% to 82.4%. Payout ratio versus NPAT: 96.6%, above normal range; 3-period mean 73.9%, range 68.2%-82.4%.
  • HY26 Payout ratio vs NPAT %: Outside range low payout ratio versus npat. 67.3%; 4-period range 68.1% to 500%. Payout ratio versus NPAT: 67.3%, below normal range; 4-period mean 179.7%, range 68.1%-500.0%.
Annual payout ratio vs EPS %—96.6%—71.1%—82.4%—68.2%—
Chart
ROE %7.8%3.2%Outside range lowOutside range low roe. 3.2%; 3-period range 6% to 11.8%. ROE: 3.2%, below normal range; 3-period mean 9.0%, range 6.0%-11.8%.0.3%Unprecedented lowUnprecedented low roe. 0.3%; 4-period range 3.7% to 9.6%. ROE: 0.3%, unprecedented low; 4-period mean 6.8%, range 3.7%-9.6%.6.0%3.7%9.3%9.6%Outside range highOutside range high roe. 9.6%; 4-period range 0.3% to 7.8%. ROE: 9.6%, above normal range; 4-period mean 4.5%, range 0.3%-7.8%.11.8%Outside range highOutside range high roe. 11.8%; 3-period range 3.2% to 9.3%. ROE: 11.8%, above normal range; 3-period mean 6.2%, range 3.2%-9.3%.6.1%
Chart
  • HY25 ROE %: Unprecedented low roe. 0.3%; 4-period range 3.7% to 9.6%. ROE: 0.3%, unprecedented low; 4-period mean 6.8%, range 3.7%-9.6%.
  • FY25 ROE %: Outside range low roe. 3.2%; 3-period range 6% to 11.8%. ROE: 3.2%, below normal range; 3-period mean 9.0%, range 6.0%-11.8%.
Net debt-$387.9m$469.2m$1b$7.4b$6.5b$6.3b—$2.3b—
Chart
Net debt / Operating profit-4.98x—17.57x48.65x—39.05x—13.84x—
Chart
Debtor days———0—1—0—
Chart
Total assets$8.8b$8.6b$8.8b$9.3b$7.9b$7.7b$7.4b$7.1b$6b
Chart

Reference: annolyse.ai/companies/hgh

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

↗
Loading chart...

The setup & the reality

FY25 → HY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Current result now available

HY26 · Released 26 February 2026

NPAT rebuilt to NZ$48.8m as the NZ lending reset rolls off

The 1255.6% headline NPAT lift is recovery from a depressed comparable; underlying NPAT of NZ$46.1m and ROE of 7.8% set the cleaner read.

Read latest briefing→

Historical setup

What FY25 said to watch

From PBT collapsed 45.3% as one-offs and provisions swamped 11.1% revenue growth

No formal ongoing targets were in force beyond the $45m underlying NPAT floor for FY2026, which management has stated guidance on an underlying basis. The result met that floor at $46.9m underlying NPAT. The strongly second-half-weighted statutory earnings profile — with $35.2m of NPAT implied in 2H2025 against just $3.6m in 1H2025 — suggests the business normalised materially following the portfolio reset, which is modestly supportive of the FY2026 guidance basis.

Whether the second-half run-rate is a reliable base depends on whether NZ credit quality has genuinely stabilised and whether the Australian banking segment can continue contributing at or above its FY2025 level. The absence of stated targets beyond the underlying NPAT floor limits the ability to assess how quickly ROE can recover toward a level that justifies the capital raised for the Australian acquisition.

Open questions

Open questions from FY25

  • What is the current arrears and provision coverage ratio across the NZ lending portfolios that were reset in 1H2025, and have they fully normalised?
  • How does the Australian banking segment's NIM of 3.01% compare to the prior period, and what is the trajectory given deposit competition and funding costs?
  • Will the 96.6% statutory payout ratio normalise in FY2026, or does the dividend policy assume a sustained recovery in underlying earnings toward a higher absolute level?
  • What specific items are expected to bridge underlying NPAT to statutory NPAT in FY2026, and how material are residual acquisition-related costs likely to be?
  • Is the NTA per share of $0.99 stable, and what is the capital adequacy position of each banking subsidiary relative to regulatory minimums?

This briefing cannot assess the credit quality trajectory of the NZ portfolio, the sustainability of the Australian segment contribution, or the pace of ROE recovery, as segment-level prior comparatives and arrears data were not available in the supplied materials.

Archive

Briefing archive

Every published Annolyse briefing for this company appears here in reverse chronological order.

HY26 · Released 26 February 2026

NPAT rebuilt to NZ$48.8m as the NZ lending reset rolls off

The 1255.6% headline NPAT lift is recovery from a depressed comparable; underlying NPAT of NZ$46.1m and ROE of 7.8% set the cleaner read.

Read briefing→

FY25 · Released 21 August 2025

PBT collapsed 45.3% as one-offs and provisions swamped 11.1% revenue growth

Revenue grew solidly but a surge in impairments, acquisition-related costs, and a portfolio reset crushed statutory earnings, leaving underlying NPAT

Read briefing→

HY25 · Released 27 February 2025

NPAT collapsed 90.4% on one-off charges, dividend halved to 2 cents

Reported NPAT of NZ$3.6m versus underlying NZ$10.7m and a 500% NPAT payout ratio leave the dividend reliant on retained earnings, not current profit.

Read briefing→

FY24 · Released 29 August 2024

PBT fell 22.0% on near-flat revenue as impairment charges bit hard

Revenue growth of just 0.2% left no buffer when provisions surged, driving a 22.0% PBT decline and compressing ROE to 6.0% from 9.3%.

Read briefing→

HY24 · Released 27 February 2024

Heartland revenue fell 2.0%, snapping a ~10% growth pattern; PBT down 23.8%

Net operating income contracted despite 4.2% receivables growth, pointing to material net interest margin compression ahead of Challenger integration.

Read briefing→

FY23 · Released 29 August 2023

PBT down 2.2% while ROE fell to 9.3% on NIM compression

Flat headline NPAT reflects a lower effective tax rate, masking underlying margin pressure and weaker returns on the expanded equity base.

Read briefing→

HY23 · Released 28 February 2023

Revenue +10.2% but NPAT just +2.5% as tax step-up and bigger equity base bite

PBT grew 6.3% on stronger margins, but a 29.5% effective tax rate and 30.5% equity expansion drove ROE down to 9.6% from 12.2%.

Read briefing→

FY22 · Released 23 August 2022

PBT up 15.5% but NPAT growth held to 9.3% by higher tax rate

Net operating income grew 11.7% and PBT expansion outpaced it, while the effective tax rate rose to 30.6% from 26.6%, narrowing the NPAT result.

Read briefing→

HY22 · Released 22 February 2022

NPAT +7.7% as lending growth lifts borrowings 32.6%

Underlying earnings progress is modest and clean, but a NZ$449m step-up in borrowings and deeply negative operating cash define the period.

Read briefing→

Related insights

Compare this company

The latest HGH metrics also appear in these cross-company views.

Insight

Dividend coverage and payout pressure

Dividend payout versus NPAT is 67.3%.

Open insight→

Insight

Revenue growth context

Revenue growth was 11.1% for this reporting period.

Open insight→

Insight

Earnings quality and statutory distortions

This result includes a statutory earnings-quality distortion flag.

Open insight→

Insight

ROE and capital efficiency

ROE was 7.8%, +7.2pp versus the prior comparable period.

Open insight→

Get notified when HGH publishes

Get the next Heartland Group Holdings result briefing and five-year history updates by email.